Oral Administration of Nanoparticles-Based TB Drugs

The Combination of Solid-State Chemistry and Medicinal Chemistry as the Basis for the Synthesis of Theranostics Platforms

“…Different dosage forms, including solutions, pastes, emulsions, and ointments, administered by methods of surface application, irrigation, and inhalations for the treatment of dental diseases, and acute and chronic inflammatory processes of periodontal tissues and oral mucosa, do not allow for the fully realized pharmacological potential of these substances. This results from the fact that saliva constantly reduces the concentration of the substances, thus diminishing their effectiveness [53]. Therefore, there is a need to use drugs with pronounced detoxification properties and prolonged duration of action-these are exactly the properties of drugs immobilized on HDS.…”

Optimization of Rifapentine-Loaded Lipid Nanoparticles Using a Quality-by-Design Strategy

“…Tuberculosis (TB) is the top infectious killer worldwide and one of the top 10 causes of deaths in 2018 [1]. The current TB treatment includes a standard six-month course of four antimicrobial drugs (i.e., rifampicin, ethambutol, isoniazid, and pyrazinamide) that, despite being effective, is associated with adverse effects [2,3]. The long treatment schedule that is required and the associated multiple side effects contribute to low patient compliance to therapy and to the appearance of multidrug-resistant strains [2,4].…”

“…No toxicity was observed in primary human macrophage viability for nanoparticles up to 1000 µg mL −1 . Overall, the optimized NLCs are efficient carriers of RPT and should be considered for further testing as promising drug delivery systems to be used in TB treatment.Pharmaceutics 2020, 12, 75 2 of 13 the TB and HIV co-epidemic, the high costs for TB patients, and the slow uptake of new effective tools constitute persistent and serious challenges in tackling the TB epidemic [1,2,6]. This fact encourages the development of new treatment regimens including other anti-TB drugs.Rifapentine (RPT) is a rifamycin derivative that has been synthesized to prolong half-life and to improve the antimycobacterial activity of rifampicin, the most effective first-line anti-TB drug [7,8].…”

“…Pharmaceutics 2020, 12, 75 2 of 13 the TB and HIV co-epidemic, the high costs for TB patients, and the slow uptake of new effective tools constitute persistent and serious challenges in tackling the TB epidemic [1,2,6]. This fact encourages the development of new treatment regimens including other anti-TB drugs.…”